Stockscreener 앱 받기
17.50
0.06%
0.01
시간 외 거래:
17.95
0.45
+2.57%
전일 마감가:
$17.49
열려 있는:
$17.46
하루 거래량:
110.85K
Relative Volume:
6.04
시가총액:
$233.44M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.86%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.50
$17.76
1주일 범위
$16.50
$17.93
52주 변동 폭
$16.50
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(858) 283-0280
주소
18575 JAMBOREE ROAD, IRVINE
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha
Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat
Analysts Offer Predictions for OKUR Q1 Earnings - Defense World
What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat
HC Wainwright Reiterates Buy Rating for OnKure Therapeutics (NASDAQ:OKUR) - MarketBeat
OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph
OnKure started at outperform by Oppenheimer, OKI-219 potential cited - MSN
OnKure shares initiated with Outperform rating on drug potential - Investing.com India
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - Benzinga
OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada
This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat
Newley merged OnKure raises $65 million - The Pharma Letter
Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera
OnKure and Reneo Pharmaceuticals complete merger - Pharmaceutical Technology
Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan
Reneo stockholders approve merger with OnKure - MSN
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | RPHM Stock News - StockTitan
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - AOL
Here's Why Everyone's Talking About Summit Therapeutics - AOL
Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results - Yahoo Finance
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc.RPHM - PR Newswire
Reneo Set to Close After Test Failure - Orange County Business Journal
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing - BioCentury
Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger - Wilson Sonsini
Reneo Pharmaceuticals and OnKure Announce Proposed Merger - GlobeNewswire
Seven biotech companies climbing their way up in Colorado - Labiotech.eu
HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech
The Week’s 10 Biggest Funding Rounds: Anthropic Generates Another Huge Round, Biotech Has Big Week - Crunchbase News
OnKure Therapeutics Announces $54 Million Series C Financing - GlobeNewswire
2023 Destination Startup® drives investment in intermountain west university innovations - University of Colorado Boulder
Biogen’s Friedl-Naderer joins Vir as CBO - BioCentury
RPHMReneo Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
OnKure, Inc. Raises $55 Million Series B Financing - Business Wire
Tyler D. Baguley - Wilson Sonsini
Immunotherapy and HDAC inhibition are anti-cancer besties - University of Colorado Anschutz Medical Campus
OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor - University of Colorado Anschutz Medical Campus
Onkure Therapeutics Inc (OKUR) 재무 분석
Onkure Therapeutics Inc (OKUR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.11%
0.26%
자본화:
|
볼륨(24시간):